Kailera Therapeutics, Inc. (KLRA) Stock

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Kailera Therapeutics, Inc. is headquartered in US.

Kailera Therapeutics, Inc. (KLRA) stock trades at $11.61 with a market capitalization of $1.50B. The stock is valued at a price-to-earnings (P/E) ratio of -6.60, price-to-book of 1.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.76 and $28.23, and currently trades 58.9% below its 52-week high.

On profitability, Kailera Therapeutics, Inc. generates a return on equity (ROE) of -55.41%, return on capital employed of -18.27%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.kailera.com